VERA - What's Going On With Vera Therapeutics Stock Today? | Benzinga
Thursday, Vera Therapeutics Inc (NASDAQ:VERA) shares closed almost 50% higher at $25.31 after the company announced 72-week data from the open-label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN).
Data from the OLE show the consistent and sustained reductions of serum galactose-deficient IgA1 (Gd-lgA1), hematuria, and urine protein to creatinine ratio (UPCR), as well as the stability of eGFR over 72 weeks in participants with IgAN.
Thursday, Oppenheimer initiated coverage on Vera Therapeutics stock with an Outperform rating and announced a price ...